Bharat Parenterals share price today

Bharat Parenterals Ltd's share price was ₹1,800.60 at the close on 4 November 2026. It has been rising for 23 weeks. That is 25.0% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹904 and ₹2,112, and at that close it sat 74% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Bharat Parenterals Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 24 weeks in a row.

Over the last 8.6 years the share price moved +924% while the NIFTY 500 moved +146%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: revenue grew again in the September 2026 quarter, best operating margin in 16 quarters and highest quarterly profit in 16 quarters.

1. Revenue grew again in the September 2026 quarter

   Revenue was ₹136 crore, +109.2% on a year earlier (₹65 crore), after 4 quarters of decline.

   Why: Revenue rose because Innoxel's licensing business grew fast.

   Next results: check whether the main standalone business turns its September order book into sales and gross profit recovers.

   From the earnings call on 30 Oct 2026.

2. Best operating margin in 16 quarters

   Operating margin was 17% in the September 2026 quarter, against 1.3% a year earlier.

   Why: Margins rose because most of each extra rupee of revenue reached profit as Innoxel's business grew.

   From the earnings call on 30 Oct 2026.

3. Highest quarterly profit in 16 quarters

   Profit of ₹12 crore in the September 2026 quarter is the highest of the last 16 quarters.

   Why: Profit hit a record because most of each extra rupee of revenue reached profit as Innoxel's business grew.

   Next results: check whether profit holds, since licensing payments are uneven and the half year gives a better read.

   From the earnings call on 30 Oct 2026.

For July to September 2026 (the quarter ended 30 September 2026), Bharat Parenterals reported revenue of ₹136 crore, up 109.2% from ₹65.0 crore a year earlier, and a profit of ₹12.0 crore, against a loss of ₹9.00 crore a year earlier.

Bharat Parenterals results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Bharat Parenterals' management discussed these results on a call held on 30 October 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Bharat Parenterals closed at ₹1,800.60 on 4 November 2026, up 50.7% from ₹1,195.00 a year earlier (7 November 2025) and up 361.8% over five years. Its highest weekly close since March 2018 was ₹2,111.50 on 28 September 2026.

Bharat Parenterals share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

437 weekly closes from 23 March 2018 to 4 November 2026.

4 Nov 2026: Bharat Parenterals closed at ₹1,800.60, down 11.2% on the week and up 4.8% on the month. 30 Oct 2026: Bharat Parenterals held its results call for July to September 2026. Management guided: Standalone revenue growth 10-15% on FY26 ₹234 crore base with operating margin 10-15%.

Earlier

• Results for July to September 2026: Revenue up 109.2% on a year earlier.
• 11 Sep 2026: ex-date for a dividend of ₹1 a share, record date 12 Sep 2026.

Bharat Parenterals paid ₹1 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.06% at the ₹1,800.60 close on 4 November 2026. The last was a dividend of ₹1 a share, ex-date 11 September 2026.

Bharat Parenterals dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Not in its latest year. Bharat Parenterals Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 2 of its last 11 reported years, so there is a history but no current dividend.

From the NSE corporate-actions record, read 5 November 2026.

On the call for July to September 2026, held on 30 October 2026, Bharat Parenterals' management guided: Standalone revenue growth 10-15% on FY26 ₹234 crore base with operating margin 10-15%.

“Innoxel's cost base is largely fixed. Between Q1 and Q2, revenue went up by 23.1 crores, and EBITDA went up by 16.5 crores. Put simply, most of each additional rupee of revenue is now flowing through to profit.”Bahim Desai, on the call for July to September 2026

What management guided

• Innoxel revenue growth 35-45% at operating margin 20-25% including out-licensing roughly ₹80-90 crores with second-half timing to decide revisit in Q3.
• Varenyam Healthcare revenue growth 20-25% at operating margin 8-13% with taper to Q4 and new division cost in band.
• Second CMO product commercialisation within FY27 upon USFDA approval with supply ramp through second half.
• First own CDMO product in October to December 2027 as 505(b)(2) plus liposomal exhibit November with filing Q1 next year.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for July to September 2026, 30 October 2026.

When Bharat Parenterals reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Standalone H2 conversion of September book and gross recovery as pre-rise pricing turns over or input costs ease.

Bharat Parenterals is on 2 of our India lists: Momentum stocks and Pharma stocks.

Bharat Parenterals Ltd earned ₹12.0 Cr of net profit in the Sep 2026 quarter. The full FY26 year was a loss of ₹27.0 Cr. That is 8.8% of the quarter's revenue. The same quarter a year earlier lost ₹9.0 Cr. 10 of the last 12 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

Bharat Parenterals Ltd reported ₹136 Cr of revenue in the Sep 2026 quarter, +109.2% on the same quarter a year earlier. Over 10 years it has grown 10.8% a year on average. The last full year, FY26, came in at ₹345 Cr. The last four reported quarters add to ₹395 Cr.

Revenue is everything the company billed its customers in the period.

FY26 revenue was ₹345 Cr, +1.5% on the year before.

Recent pace: the last four quarters grew +19.2% on average, against 10.8% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +10.6%, against +16.1% a year over the last 8 quarters (rolling over).

Bharat Parenterals Ltd's operating margin was 17.0% in the Sep 2026 quarter, 15.7 percentage points higher than the same quarter a year ago. Across 11 years it has been between 1.1% and 14.0%. The latest quarter is above every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +16.0 percentage points on the year while gross margin changed −8.7 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 33% of Bharat Parenterals Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹38.0 Cr of operating cash against −₹27.0 Cr of profit. After ₹41.0 Cr of spending on assets, free cash was −₹3.0 Cr: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 33% of profit came in as cash: the cash cycle got 88 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page.

What to look at next: less of the profit turns into cash than it should, and the cash cycle is 88 days longer. The next section looks at where the cash is stuck.

Bharat Parenterals Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 199 days in FY26, up from 111 days in FY21. It spent ₹227 Cr on assets over the last 3 years. Customers take 159 days to pay, and stock sits for 162 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹345 Cr, each day of that cycle ties up about ₹0.9 Cr, so roughly ₹188 Cr is tied up in the business at any time.

FY26: customers took 159 days to pay and stock sat for 162 days, about 5.3 months of sales sitting as stock, for a full cycle of 199 days, longer than FY21's 111.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 162 days. Customers pay about 159 days after that. Suppliers are paid at 122 days. Together that makes the 199-day cycle.

Spending on assets: ₹227 Cr over the last 3 years, against ₹78.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹35.0 Cr (FY26): assets paid for that are not earning yet.

In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit.

Bharat Parenterals Ltd's P/E is 1,000.5×, about the highest it has ever been. Its usual P/E (the middle reading) is 11.1×, over 6.2 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

Where the price move came from: over 5 years the price moved +35.8% a year; about +13.4% a year came from earnings growth and about +22.4 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.

A quarterly PEG curve, which only the second data source has, is not shown on this page: its two data sources disagree by up to 989% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.

Bharat Parenterals Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 9 quarters of 2 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Bharat Parenterals Ltd earned a ROCE of −2% in FY26. That is up from a low of −4% in FY25. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a −7.8% net margin and 0.56× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a −7.8% net margin × 0.56× asset turnover × 1.90× leverage (assets divided by equity) ≈ −8.3% on equity. The margin does its share; borrowing is a big part of it.

The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 989% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.

Bharat Parenterals Ltd had ₹146 Cr of borrowings against ₹322 Cr of equity in FY26, so its debt is 0.45× its equity. Its operating profit is 1 times its interest bill. Over 5 years borrowings went from ₹12.0 Cr to ₹146 Cr. Over the last 3 of those years it spent ₹227 Cr on assets.

Debt-to-equity shows how much of the business is paid for with borrowed money. Interest cover shows how many times operating profit pays the interest bill. Low debt and high cover are the safe combination.

Part of the spending on assets is being paid for with borrowed money.

The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 989% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.

Promoters raised their stake in Bharat Parenterals Ltd by 1.9 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 67.2% of the company. Domestic institutions moved +0.7 points over the same period, to 1.3%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Promoters: +1.9 points over 8 quarters, to 67.2%; Domestic institutions: +0.7 points over 8 quarters, to 1.3%; Foreign institutions: +0.0 points over 8 quarters, to 0.1%.

Why the owners changed: promoters drove it (+1.9 points), together with domestic institutions (+0.7 points). They raised their stake step by step.

For Bharat Parenterals Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

45.9 out of 100, rank 27 of 44 in Pharma - Formulators, with 52% of the evidence available.

Bharat Parenterals Ltd scores 45.9 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 27. Some evidence is missing, so the score is pulled toward the middle on purpose.

The four parts add up to the total exactly: 19.9 + 5.3 + 8.5 + 12.2 = 45.9. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Bharat Parenterals ranks 27 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 45.9 out of 100.